Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 05 December 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Response to therapy among patients with acute exacerbation of chronic Hep C

The latest issue of Clinical Gastroenterology & Hepatology investigates clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic Hepatitis C.

News image

The slow asymptomatic progression of chronic hepatitis C can be interrupted by an acute exacerbation, characterized by increased serum levels of alanine aminotransferase and bilirubin and other symptoms of acute hepatitis.

Dr Evangelista Sagnelli and colleagues provided more information about the clinical presentation of acute exacerbation of chronic hepatitis C.

The research team identified 82 consecutive patients, from 2 locations in Italy, who had an acute exacerbation of chronic hepatitis C from 2005 through 2010.

The team followed them up for a median period of 36 months.

Hepatitis C virus genotype 2 was detected in 46% of cases
Clinical Gastroenterology and Hepatology

These cases were hepatitis C virus RNA positive, hepatitis B surface antigen-negative, and had not received anti-hepatitis C virus therapy.

The cases were matched with 82 subjects with hepatitis C without reactivation for age, sex, and hepatitis C virus genotype.

The researchers followed 69 cases, and 73 controls were followed up for at least 2 years.

Liver biopsy specimens had been taken from 23 cases and 31 controls—once before enrollment in the study and once during the follow-up period.

The research team detected hepatitis C virus genotype 2 in 46% of cases, and hepatitis C virus genotype 1 was detected in 44%.

Among cases, the mean alanine aminotransferase level was 1063 IU/dL, and the mean total bilirubin level was 16 mg/dL.

The doctors analyzed a higher percentage of cases carried the interleukin-28B CC genotype than controls.

Among cases, 44% had a steady increase in alanine aminotransferase level for 56% of these patients, alanine aminotransferase levels returned to baseline values before the acute exacerbation of chronic hepatitis.

Based on comparisons of biopsy specimens, 18 cases and 11 controls had increasing fibrosis, with Ishak scores increasing by more than 2.

The team found that 14 cases and 3 controls had increases in necroinflammation of more than 2 points.

The researchers observed that 32 cases and 38 controls received treatment with pegylated interferon and ribavirin.

A sustained virologic response was achieved in 26 cases and 23 controls.

Dr Sagnelli's team commented, "Although an acute exacerbation of chronic hepatitis is a serious medical condition, most patients achieve a sustained virologic response after treatment with pegylated interferon and ribavirin."

Clin Gastroenterol and Hepatol 2013: 11(9): 1174-1180
19 September 2013

Go to top of page Email this page Email this page to a colleague

 05 December 2016 
Disease mangement in IBD
 05 December 2016 
New biomarkers for IBD diagnosis
 05 December 2016 
Reducing hospitalization in IBD
 02 December 2016 
Hep E in acute liver failure
 02 December 2016 
Occurrence and severity of alcoholic hepatitis
 02 December 2016 
Food antigen in active eosinophilic esophagitis
 01 December 2016 
Iron deficiency in anemic ulcerative colitis patients
 01 December 2016 
Prognostic factors after paracetamol-induced liver failure
 01 December 2016 
Factors that influence colorectal cancer screening findings
 30 November 2016 
Certolizumab pegol in Crohn's disease
 30 November 2016 
Genetic risk of Crohn's in chronic granulomatous disease
 30 November 2016 
Rifaximin in diarrhea-predominant IBS
 29 November 2016 
Assessing liver steatosis
 29 November 2016 
Treating Zenker's diverticulum
 29 November 2016 
Colorectal cancer surveillance in ulcerative colitis
 28 November 2016 
Complications in celiac disease
 28 November 2016 
Monitoring IBD with mobile technology
 28 November 2016 
Reducing warfarin-related upper GI bleeds
 25 November 2016 
Metal vs plastic stents for pancreatic cancer surgery
 25 November 2016 
Yoga and IBS therapy 
 25 November 2016 
Colorectal cancer screening issues
 24 November 2016 
Partner burden in celiac disease
 24 November 2016 
Fusobacterium nucleatum for colorectal cancer prognosis
 24 November 2016 
PPIS and gastric cancer risk
 23 November 2016 
Diagnosing autoimmune pancreatitis
 23 November 2016 
Readmissions in cirrhosis
 23 November 2016 
Quality assurance standards for colonoscopy
 22 November 2016 
Fatigue in IBD
 22 November 2016 
PPIs and C. diff in ICU 
 22 November 2016 
Bile acid diarrhea in function bowel disorder with diarrhea
 21 November 2016 
Financial incentives and colorectal cancer screening
 21 November 2016 
Pain after endoscopic resection of gastric tumors
 21 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 18 November 2016 
Colorectal cancer risk and self-reported family history
 18 November 2016 
Ustekinumab in Crohn’s disease
 18 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 17 November 2016 
Risk of overweight in infants
 17 November 2016 
Moderate alcohol consumption and NAFLD
 17 November 2016 
Liver-related specialty care in patients with Hep C
 16 November 2016 
PPI therapy in liver disease
 16 November 2016 
Education in Gastroenterology fellowship
 16 November 2016 
Paternal preconceptional use of anti-TNF-α agents
 15 November 2016 
Novel treatment of NASH 
 15 November 2016 
Physician perspectives on Hep C management
 15 November 2016 
Contraceptives and ulcerative colitis
 14 November 2016 
Cardiovascular risk in NAFLD 
 14 November 2016 
Vit D and NAFLD
 14 November 2016 
Malignancy risk in IBD 
 11 November 2016 
Treatment of Hep C along with opioid agonist therapy
 11 November 2016 
Diabetes and liver cancer risk in Hep C cirrhosis
 11 November 2016 
Biomarker of cirrhosis progression
 10 November 2016 
Testosterone levels and cirrhosis outcomes in men
 10 November 2016 
Improving bowel quality before colonoscopy
 10 November 2016 
Fecal microbiota transplantation and CDI episodes
 09 November 2016 
Minimizing costs of esophagogastroduodenoscopy and colonoscopy
 09 November 2016 
Risk of TB in IBD patients receiving therapy
 09 November 2016 
Liver transplant wait-list and mortality in infants
 08 November 2016 
NSAIDS and risk of Barrett’s
 08 November 2016 
Ferritin levels and NAFLD mortality
 08 November 2016 
Alarms in the diagnosis of colorectal cancer

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us